XML 107 R95.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information - Summary of Net Sales by Segment and Geographical Area (Details) - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Disclosure of geographical areas [line items]    
Net sales € 19,889 € 18,360 [1],[2]
Other revenues 1,452 1,529 [2],[3]
Cost of sales (5,881) (5,966) [2]
Research and development expense (3,717) (3,335) [2]
Selling, general and administrative expense (4,506) (4,303) [2]
Attributable to non-controlling interests 25 17 [2]
Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations [4] (158) (85)
Opella Business    
Disclosure of geographical areas [line items]    
Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations 88  
Biopharma Segment [Member]    
Disclosure of geographical areas [line items]    
Net sales 19,889 18,360 [1],[5]
Business operating income 5,347 4,916 [5]
Other revenues 1,246 1,352 [3],[5]
Cost of sales (5,753) (5,849) [5]
Research and development expense (3,716) (3,334) [5]
Selling, general and administrative expense (4,447) (4,247) [5]
Miscellaneous Other Operating Income (Expenses) (1,941) (1,426) [5]
Share of profit (loss) of associates and joint ventures accounted for using equity method 77 66 [5]
Attributable to non-controlling interests (8) (6) [5]
Biopharma Segment [Member] | Dupixent    
Disclosure of geographical areas [line items]    
Net sales 7,312 6,138 [1]
Biopharma Segment [Member] | Aubagio    
Disclosure of geographical areas [line items]    
Net sales 138 209 [1]
Biopharma Segment [Member] | Polio Pertussis Hib Vaccines [Member]    
Disclosure of geographical areas [line items]    
Net sales 1,361 1,348 [1]
Biopharma Segment [Member] | Influenza Vaccines [Member]    
Disclosure of geographical areas [line items]    
Net sales 214 188 [1]
Biopharma Segment [Member] | Nexviazyme    
Disclosure of geographical areas [line items]    
Net sales 387 320 [1]
Biopharma Segment [Member] | Sarclisa    
Disclosure of geographical areas [line items]    
Net sales 276 227 [1]
Biopharma Segment [Member] | Altuviiio    
Disclosure of geographical areas [line items]    
Net sales 542 280 [1]
Biopharma Segment [Member] | Rezurock    
Disclosure of geographical areas [line items]    
Net sales 263 207 [1]
Biopharma Segment [Member] | Cablivi    
Disclosure of geographical areas [line items]    
Net sales 136 113 [1]
Biopharma Segment [Member] | Xenpozyme    
Disclosure of geographical areas [line items]    
Net sales 110 72 [1]
Biopharma Segment [Member] | Tzield    
Disclosure of geographical areas [line items]    
Net sales 29 21 [1]
Biopharma Segment [Member] | RSV Vaccines    
Disclosure of geographical areas [line items]    
Net sales 356 200 [1]
Biopharma Segment [Member] | Meningitis Travel And Endemic Vaccines    
Disclosure of geographical areas [line items]    
Net sales 609 583 [1]
Other segment    
Disclosure of geographical areas [line items]    
Net sales [6] [5]
Business operating income 16 [6] 22 [5]
Other revenues 206 [6] 177 [5]
Cost of sales (128) [6] (110) [5]
Research and development expense (1) [6] (1) [5]
Selling, general and administrative expense (59) [6] (56) [5]
Miscellaneous Other Operating Income (Expenses) (2) [6] 12 [5]
Share of profit (loss) of associates and joint ventures accounted for using equity method 0 [6] 0 [5]
Attributable to non-controlling interests 0 [6] 0 [5]
Other Products Segment | Industrial Sales [Member]    
Disclosure of geographical areas [line items]    
Net sales 251 274 [1]
Europe [Member]    
Disclosure of geographical areas [line items]    
Net sales 4,144 4,072 [7]
Europe [Member] | Biopharma Segment [Member]    
Disclosure of geographical areas [line items]    
Net sales 4,144 4,072
Europe [Member] | Biopharma Segment [Member] | Dupixent    
Disclosure of geographical areas [line items]    
Net sales 944 770
Europe [Member] | Biopharma Segment [Member] | Aubagio    
Disclosure of geographical areas [line items]    
Net sales 40 95
Europe [Member] | Biopharma Segment [Member] | Polio Pertussis Hib Vaccines [Member]    
Disclosure of geographical areas [line items]    
Net sales 223 248
Europe [Member] | Biopharma Segment [Member] | Influenza Vaccines [Member]    
Disclosure of geographical areas [line items]    
Net sales 52 30
Europe [Member] | Biopharma Segment [Member] | Nexviazyme    
Disclosure of geographical areas [line items]    
Net sales 132 95
Europe [Member] | Biopharma Segment [Member] | Sarclisa    
Disclosure of geographical areas [line items]    
Net sales 83 64
Europe [Member] | Biopharma Segment [Member] | Altuviiio    
Disclosure of geographical areas [line items]    
Net sales 0 0
Europe [Member] | Biopharma Segment [Member] | Rezurock    
Disclosure of geographical areas [line items]    
Net sales 23 12
Europe [Member] | Biopharma Segment [Member] | Cablivi    
Disclosure of geographical areas [line items]    
Net sales 55 43
Europe [Member] | Biopharma Segment [Member] | Xenpozyme    
Disclosure of geographical areas [line items]    
Net sales 44 24
Europe [Member] | Biopharma Segment [Member] | Tzield    
Disclosure of geographical areas [line items]    
Net sales 1 1
Europe [Member] | Biopharma Segment [Member] | RSV Vaccines    
Disclosure of geographical areas [line items]    
Net sales 85 7
Europe [Member] | Biopharma Segment [Member] | Meningitis Travel And Endemic Vaccines    
Disclosure of geographical areas [line items]    
Net sales 96 97
Europe [Member] | Other Products Segment | Industrial Sales [Member]    
Disclosure of geographical areas [line items]    
Net sales 241 273
UNITED STATES    
Disclosure of geographical areas [line items]    
Net sales 9,535 8,292 [7]
UNITED STATES | Biopharma Segment [Member]    
Disclosure of geographical areas [line items]    
Net sales 9,535 8,292
UNITED STATES | Biopharma Segment [Member] | Dupixent    
Disclosure of geographical areas [line items]    
Net sales 5,283 4,437
UNITED STATES | Biopharma Segment [Member] | Aubagio    
Disclosure of geographical areas [line items]    
Net sales 76 96
UNITED STATES | Biopharma Segment [Member] | Polio Pertussis Hib Vaccines [Member]    
Disclosure of geographical areas [line items]    
Net sales 320 311
UNITED STATES | Biopharma Segment [Member] | Influenza Vaccines [Member]    
Disclosure of geographical areas [line items]    
Net sales 54 16
UNITED STATES | Biopharma Segment [Member] | Nexviazyme    
Disclosure of geographical areas [line items]    
Net sales 195 174
UNITED STATES | Biopharma Segment [Member] | Sarclisa    
Disclosure of geographical areas [line items]    
Net sales 119 100
UNITED STATES | Biopharma Segment [Member] | Altuviiio    
Disclosure of geographical areas [line items]    
Net sales 456 259
UNITED STATES | Biopharma Segment [Member] | Rezurock    
Disclosure of geographical areas [line items]    
Net sales 220 188
UNITED STATES | Biopharma Segment [Member] | Cablivi    
Disclosure of geographical areas [line items]    
Net sales 71 60
UNITED STATES | Biopharma Segment [Member] | Xenpozyme    
Disclosure of geographical areas [line items]    
Net sales 47 37
UNITED STATES | Biopharma Segment [Member] | Tzield    
Disclosure of geographical areas [line items]    
Net sales 27 20
UNITED STATES | Biopharma Segment [Member] | RSV Vaccines    
Disclosure of geographical areas [line items]    
Net sales 68 116
UNITED STATES | Biopharma Segment [Member] | Meningitis Travel And Endemic Vaccines    
Disclosure of geographical areas [line items]    
Net sales 319 301
UNITED STATES | Other Products Segment | Industrial Sales [Member]    
Disclosure of geographical areas [line items]    
Net sales 1 1
Other Countries [member]    
Disclosure of geographical areas [line items]    
Net sales 6,210 5,996
Other Countries [member] | Biopharma Segment [Member]    
Disclosure of geographical areas [line items]    
Net sales 6,210 5,996
Other Countries [member] | Biopharma Segment [Member] | Dupixent    
Disclosure of geographical areas [line items]    
Net sales 1,085 931
Other Countries [member] | Biopharma Segment [Member] | Aubagio    
Disclosure of geographical areas [line items]    
Net sales 22 18
Other Countries [member] | Biopharma Segment [Member] | Polio Pertussis Hib Vaccines [Member]    
Disclosure of geographical areas [line items]    
Net sales 818 789
Other Countries [member] | Biopharma Segment [Member] | Influenza Vaccines [Member]    
Disclosure of geographical areas [line items]    
Net sales 108 142
Other Countries [member] | Biopharma Segment [Member] | Nexviazyme    
Disclosure of geographical areas [line items]    
Net sales 60 51
Other Countries [member] | Biopharma Segment [Member] | Sarclisa    
Disclosure of geographical areas [line items]    
Net sales 74 63
Other Countries [member] | Biopharma Segment [Member] | Altuviiio    
Disclosure of geographical areas [line items]    
Net sales 86 21
Other Countries [member] | Biopharma Segment [Member] | Rezurock    
Disclosure of geographical areas [line items]    
Net sales 20 7
Other Countries [member] | Biopharma Segment [Member] | Cablivi    
Disclosure of geographical areas [line items]    
Net sales 10 10
Other Countries [member] | Biopharma Segment [Member] | Xenpozyme    
Disclosure of geographical areas [line items]    
Net sales 19 11
Other Countries [member] | Biopharma Segment [Member] | Tzield    
Disclosure of geographical areas [line items]    
Net sales 1 0
Other Countries [member] | Biopharma Segment [Member] | RSV Vaccines    
Disclosure of geographical areas [line items]    
Net sales 203 77
Other Countries [member] | Biopharma Segment [Member] | Meningitis Travel And Endemic Vaccines    
Disclosure of geographical areas [line items]    
Net sales 194 185
Other Countries [member] | Other Products Segment | Industrial Sales [Member]    
Disclosure of geographical areas [line items]    
Net sales € 9 € 0
[1] Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[2] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3]
(a)    Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[4]
(b) In 2025, this line includes an expense of €88 million related to the tax impact on the gain arising on the loss of control of Opella.
[5] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[6]
[7]
(a)    Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.